Palivizumab for preventing serious lower respiratory tract disease caused by respiratory syncytial virus

Published on 08 Feb 2023
Last Updated on 08 Feb 2023

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended palivizumab for inclusion on the MOH List of Subsidised Drugs for prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease, because it does not represent a cost-effective use of healthcare resources at the price proposed by the company.

Palivizumab for preventing serious lower respiratory tract disease caused by respiratory syncytial virus (Published 8 Feb 2023) [PDF, 126 KB]

PES Palivizumab for preventing serious lower respiratory tract disease caused by respiratory syncytial virus (Published 8 Feb 2023) [PDF, 114 KB]